Ultragenyx Correlations
RARE Stock | USD 48.13 0.77 1.63% |
The current 90-days correlation between Ultragenyx and Mirati Ther is 0.23 (i.e., Modest diversification). The correlation of Ultragenyx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Ultragenyx Correlation With Market
Modest diversification
The correlation between Ultragenyx and DJI is 0.27 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ultragenyx and DJI in the same portfolio, assuming nothing else is changed.
Ultragenyx |
Moving together with Ultragenyx Stock
0.67 | FDMT | 4D Molecular Therapeutics | PairCorr |
0.9 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.92 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.7 | IVVD | Invivyd | PairCorr |
0.78 | MREO | Mereo BioPharma Group | PairCorr |
0.86 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
0.63 | PDSB | PDS Biotechnology Corp | PairCorr |
0.92 | PEPG | PepGen | PairCorr |
0.78 | ADAP | Adaptimmune Therapeutics | PairCorr |
0.75 | ANEB | Anebulo Pharmaceuticals | PairCorr |
0.73 | BDTX | Black Diamond Therap | PairCorr |
0.87 | COLL | Collegium Pharmaceutical | PairCorr |
Moving against Ultragenyx Stock
0.88 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.81 | NAMS | NewAmsterdam Pharma | PairCorr |
0.49 | PMVP | Pmv Pharmaceuticals | PairCorr |
0.39 | PHVS | Pharvaris BV | PairCorr |
0.36 | ESLAW | Estrella Immunopharma | PairCorr |
0.83 | AVTE | Aerovate Therapeutics | PairCorr |
0.83 | VREX | Varex Imaging Corp | PairCorr |
0.78 | SGMO | Sangamo Therapeutics Buyout Trend | PairCorr |
0.74 | CRVS | Corvus Pharmaceuticals | PairCorr |
0.71 | AGIO | Agios Pharm | PairCorr |
0.41 | ANTX | AN2 Therapeutics | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ultragenyx Stock performing well and Ultragenyx Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ultragenyx's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
XFOR | 5.04 | (0.48) | 0.00 | (0.23) | 0.00 | 8.82 | 62.35 | |||
TERN | 3.39 | (0.35) | 0.00 | (0.23) | 0.00 | 6.02 | 34.09 | |||
DAWN | 2.05 | (0.11) | 0.00 | (0.02) | 0.00 | 3.84 | 11.44 | |||
PDSB | 3.34 | (0.65) | 0.00 | (0.27) | 0.00 | 7.67 | 31.83 | |||
INZY | 2.76 | (1.20) | 0.00 | (0.59) | 0.00 | 5.07 | 16.62 | |||
MRTX | 2.24 | (0.50) | 0.00 | (0.67) | 0.00 | 4.02 | 16.13 | |||
AMLX | 4.33 | 1.51 | 0.31 | 1.33 | 4.07 | 10.06 | 33.56 | |||
APLS | 2.51 | (0.25) | 0.00 | (0.26) | 0.00 | 4.48 | 15.97 | |||
CRNX | 1.71 | 0.00 | 0.00 | 0.12 | 2.47 | 3.67 | 16.75 | |||
ARVN | 2.55 | (0.17) | (0.02) | 0.03 | 3.44 | 4.85 | 17.13 |
Ultragenyx Corporate Management
Dennis Huang | Chief Technical Operations Officer and Sr. VP | Profile | |
Theodore Huizenga | Corporate VP | Profile | |
Arjun Natesan | Vice Research | Profile | |
Vimal Srivastava | Senior Management | Profile | |
Aaron Olsen | Senior Finance | Profile | |
Paul JD | Vice Property | Profile |